Where Is The Patient Voice In Alzheimer's Disease Drug Development?
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies focused on Alzheimer's R&D need to catch up on patient involvement, and earlier diagnosis may help, patient advocate suggests.
You may also be interested in...
Lilly Shifts Course With Alzheimer’s Drug Solanezumab
In another sign of uncertainty for Alzheimer’s disease drug development, Lilly shakes things up with announcement of design changes for Phase III trial for solanezumab.
Alzheon Revives Failed Alzheimer's Drug With Genetic Subtype Approach
Phase III data presented in Athens shows clinical benefit for cognition and/or function in patients who are homozygous or heterozygous for the APOE4 gene.
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.